Physician profile
Chandra Venugopal
NPI 1013917541
$3,896.40
in general payments reported to CMS, 2019-2025
27 companies · $833 in 2025
The $833 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $118 · 2021: $946 · 2022: $538 · 2023: $277 · 2024: $558 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,649 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,649.04 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $569.02 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $408.40 | 2019-2024 | Camzyos, Eliquis |
| Amgen INC. | $300.34 | 2019-2022 | |
| Abbott Laboratories | $293.60 | 2020-2025 | Ensite, Cardiomems, Aveir |
| Astellas Pharma US INC | $226.48 | 2021 | |
| Esperion Therapeutics, INC. | $224.41 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $204.64 | 2021-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $203.80 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $194.14 | 2019-2024 | |
| Kestra Medical Technology Services, INC. | $191.30 | 2023-2025 | Assure Wcd |
| Boston Scientific Corporation | $146.03 | 2021-2025 | Watchman Flx, Watchman Access System, Ams 700 |
| Cvrx, INC. | $133.83 | 2023-2025 | Barostim Neo System |
| Pfizer INC. | $125.19 | 2019-2024 | |
| Bard Peripheral Vascular, INC. | $115.83 | 2022 | |
| Sanofi-Aventis U.S. LLC | $96.11 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $82.21 | 2021 | |
| Heartflow, INC. | $71.67 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $59.18 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $56.27 | 2023-2024 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $42.83 | 2019-2021 | |
| Cleerly, INC. | $35.10 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Lexicon Pharmaceuticals, INC. | $25.53 | 2024 | |
| Amarin Pharma, INC. | $23.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.96 | 2019 | |
| Becton, Dickinson and Company | $15.83 | 2024 | Venclose Maven Catheter |
| Edwards Lifesciences Corporation | $15.51 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Venugopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.